Sign In   |   Register
News: Congress

Focus on EAS Innsbruck 2016: Introducing the faculty - Plenary speaker Matthias H. Tschöp

04 January 2016   (0 Comments)
Share |

A forward-looking scientific Programme to excite, inspire and inform!

The EAS 2016 Scientific Committee has created a programme featuring ground-breaking speakers in their respective fields. EAS 2016 Innsbruck welcomes a distinguished international faculty to share their forward-looking perspectives on the latest developments in basic research and clinical practice in atherosclerosis and cardiovascular disease. You can find details of the Plenary and Workshop sessions now on the Congress website, www.eas2016.kenes.com.

Abstract submission is now open. Submit your abstract by January 11, 2016 for the opportunity to present your findings at this prestigious international Congress.

Here, in a series of newsletters, we introduce members of the EAS 2016 Innsbruck faculty.

Plenary session 3, Wednesday, June 01, 2016: Future Therapeutic Challenges

Matthias H. Tschöp, Germany: Drugs for metabolic disorders and obesity

Matthias Tschöp is Research Director of the Helmholtz Diabetes Center and Director of the Institute for Diabetes and Obesity, Helmholtz Zentrum München, Germany. He also holds the Chair of the Division of Metabolic Diseases at Technische Universität München, and is Adjunct Professor at Yale University, New Haven, Connecticut, USA. Professor Tschöp received his M.D. from Ludwig-Maximilians-Universität in Munich, and completed a postdoctoral fellowship at the Eli Lilly Research Laboratories, USA.  After establishing his independent research laboratory at the German Institute of Human Nutrition Potsdam-Rehbrücke in Germany in 2002 and 2003, he returned to Cincinnati where he led a research institute as a tenured Professor of Endocrinology and Diabetes at the University of Cincinnati Metabolic Diseases Institute.  Until 2009, Professor Tschöp was the Arthur Russell Morgan Endowed Chair of Medicine and Research Director of the University of Cincinnati’s Metabolism Center of Excellence for Diabetes and Obesity. His research focuses on molecular investigation of diabetes and obesity. A key area of interest is the role of gut-brain communication in the regulation of adiposity, glucose homeostasis and energy metabolism. Professor Tschöp is the recipient of numerous awards including the Alexander von Humboldt Professorship, the highest-endowed German research award, in 2012.

The escalating pandemics of diabetes and obesity substantially impact morbidity, mortality and healthcare costs. Beyond lifestyle, the cornerstone of management, and bariatric surgery for management of obesity, pharmacotherapeutics options are so far limited.

The ideal anti-obesity drug would produce sustained weight loss with minimal side effects. However, given that the mechanisms that regulate energy balance overlap with other physiological functions, and are also influenced by a range of factors that compromise the efficacy of pharmacological interventions, it is not surprising that anti-obesity drug discovery research and development is littered with failure. Additionally, side effects have proved to be an issue with a number of new agents.

New treatments for obesity that are both better tolerated and more efficacious are therefore urgently needed. In this context, advances in understanding of the basic neurobiology of hunger and satiety, especially in the case of ghrelin, cholecystokinin (CCK), peptide YY (PYY) and glucagon-like peptide-1 (GLP-1), and of homeostatic mechanisms related to leptin and its upstream pathways in the hypothalamus, suggest new potential. Of note, GLP-1 receptor agonists are promising, not only because these agents are now available as diabetes treatments but also because of potential body-weight-lowering effects in humans. It is likely that the development of efficacious and safe anti-obesity treatments will require multiple strategies to allow for the tailoring of therapy to the individual to ensure the sustainability of weight loss.  

References

Schwenk RW, Baumeier C, Finan B, Kluth O, Brauer C, Joost HG, DiMarchi RD, Tschöp MH, Schürmann A. GLP-1-oestrogen attenuates hyperphagia and protects from beta cell failure in diabetes-prone New Zealand obese (NZO) mice. Diabetologia 2015;58:604-14

Finan B, Yang B, Ottaway N, Smiley DL, Ma T, Clemmensen C, Chabenne J, Zhang L, Habegger KM, Fischer K, Campbell JE, Sandoval D, Seeley RJ, Bleicher K, Uhles S, Riboulet W, Funk J, Hertel C, Belli S, Sebokova E, Conde-Knape K, Konkar A, Drucker DJ, Gelfanov V, Pfluger PT, Müller TD, Perez-Tilve D, DiMarchi RD, Tschöp MH. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 2015;21:27-36.

Pfluger PT, Kabra DG, Aichler M, Schriever SC, Pfuhlmann K, García VC, Lehti M, Weber J, Kutschke M, Rozman J, Elrod JW, Hevener AL, Feuchtinger A, Hrabě de Angelis M, Walch A, Rollmann SM, Aronow BJ, Müller TD, Perez-Tilve D, Jastroch M, De Luca M, Molkentin JD, Tschöp MH. Calcineurin links mitochondrial elongation with energy metabolism.  Cell Metab 2015 Sep 23. [Epub ahead of print]


Membership Software Powered by YourMembership  ::  Legal